Maze Therapeutics, Inc. 4

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, sold 9,705 shares of common stock for roughly $254,500 under a Rule 10b5-1 plan.

On September 4, 2026, Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, Inc., sold 9,705 shares of the company’s common stock in an open-market transaction under a pre-established Rule 10b5-1 trading plan. The shares were sold at a weighted average price of approximately $26.22 per share, within a reported trading range of $25.77 to $26.42, for an estimated total value of about $254,500. Following this planned sale, Bernstein’s remaining direct common stock holdings are reported as zero shares, indicating a full disposition of his directly held common stock in this transaction.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0002050172-26-000036

Alert Tier

6